Emerging drugs for chronic myeloid leukemia

Bibliography

• Chronic myelogenous leukemia V.I.2008. NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network, 2008. Available from: www.nccn.org/professionals/physician_gls/PDF/cml.pdf. [Last accessed 19 September 2008]
   Google Scholar
• Baccarani M, Cortes J, Pane F, Chronic Myeloid Leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041-51
   PubMed Web of Science ®Google Scholar
• Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007;7:441-53
   PubMed Web of Science ®Google Scholar
• Daley GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by 210 bcr-abl gene of the Philadelphia chromosome. Science 1990;87:6649-53
   Google Scholar
• Elefanty AG, Hariharan IK, Cory S. Bcr-Abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice. EMBO J 1990;9:1069-78
   PubMed Web of Science ®Google Scholar
• Kelliher MA, McLaughlin J, Witte ON, Rosenberg N. Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci USA 1990;87:6649-53
   PubMed Web of Science ®Google Scholar
• Pear WS, Miller JP, Xu L, Efficient and rapid induction of a chronic myelogenous leukemia-like disease in mice receiving p210bcr-abl-transformed bone marrow. Blood 1998;92:3780-92
   PubMed Web of Science ®Google Scholar
• Heisterkamp N, Jenster G, ten Hoeve J. Acute leukaemia in bcr/abl transgenic mice. Nature 1990;344:251-3
   PubMed Web of Science ®Google Scholar
• Heisterkamp N, Jenster G, ten Hoeve J. Acute leukaemia in bcr/abl transgenic mice. Nature 1990;344:251-3
   PubMed Web of Science ®Google Scholar
• Ben-Neriah Y, Daley G Q, Mes-Masson A, The chronic myelogenous leukemiaspecific p210 protein is the product of the bcr-abl hybrid gene Science 1986;233:212-4
   PubMed Web of Science ®Google Scholar
• Cortes J. Natural history and staging of chronic myelogenous leukemia. Hematol Oncol Clin North Am 2004;18:569-84
   PubMed Web of Science ®Google Scholar
• Melo J.V. The diversity of Bcr-Abl fusion proteins and their relationship to leukemia phenotype. Blood 1996;88:2375-84
   PubMed Web of Science ®Google Scholar
• Gratwohl A, Brand R, Apperley J, Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006;91:513-21
   PubMed Web of Science ®Google Scholar
• Guilhot F, Chastang C, Michallet M, Interferon alpha-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl J Med 1997;337:223-9
   PubMed Web of Science ®Google Scholar
• Giralt SA, Arora M, Goldman JM, Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. Br J Haematol 2007;137:461-7
   PubMed Web of Science ®Google Scholar
• Cohen MH, Williams G, Johnson JR, Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002;8:935-42
   PubMed Web of Science ®Google Scholar
• Druker BJ, Talpaz M, Resta D, Efficacy and safety of a specific inhibitor of the Bcr-Abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7
   PubMed Web of Science ®Google Scholar
• Druker BJ, Sawyers CL, Kantarjian H, Activity of a specific inhibitor of the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukaemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Sawyers C, Hochhaus A, Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. New Engl J Med 2002;346:645-52
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Druker B, Sawyers C, Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukaemia after failure of interferon-alpha treatment. Blood 2008;111:1039-43
   PubMed Web of Science ®Google Scholar
• Sawyers CL, Hochhaus A, Feldman E, Imatinib induces hematologic and cytogenetic responses in patients with chronic myeloid leukaemia in myeloid blast crisis: results of a phase II study. Blood 2002;99:3530-9
   PubMed Web of Science ®Google Scholar
• Talpaz M, Silver RT, Druker BJ, Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99:1928-37
   PubMed Web of Science ®Google Scholar
• O'Brien SG, Guilhot F, Larson RA, Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O'Brien SG, Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17
   PubMed Web of Science ®Google Scholar
• Volpe G, Panuzzo C, Ulisciani S, Cilloni D. Imatinib resistance in CML Cancer Lett 2009;274:1-9
   PubMed Web of Science ®Google Scholar
• Baccarani M, Saglio G, Goldman J, Evolving concepts in themanagement of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-20
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Kantarjian H, Baccarani M, Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007;109:2303-9
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Giles F, Gattermann N, Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007;110:3540-6
   PubMed Web of Science ®Google Scholar
• Lombardo LJ, Lee FY, Chen P, Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin- 4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004;47:6658-61
   PubMed Web of Science ®Google Scholar
• Mauro MJ, Baccarani M, Cervantes F, Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). J Clin Oncol 2008;26: abstract 7009
   Web of Science ®Google Scholar
• Porkka K, Martinelli G, Ottmann O, Dasatinib efficacy in patients with imatinib-resistant/-intolerant Philadelphia-chromosome-positive acute lymphoblastic leukemia: 24-month data from START-L. Haematologica 2008;93s1:1 abstract 001
   Google Scholar
• Rea D, Dombret H, Kim DW, Dasatinib efficacy in patients with imatinib-resistant/-intolerant chronic myeloid leukemia in accelerated phase 24-month data from START-A. Haematologica 2008;93s1:391 abstract 0982
   Google Scholar
• Saglio G, Dombret H, Rea D, Dasatinib efficacy in patients with imatinib-resistant/-intolerant chronic myeloid leukemia in blast phase: 24- month data from the START program. Haematologica 2008;93s1:349 abstact 0880
   Google Scholar
• Hochhaus A, Branford S, Radich J, Efficacy of dasatinib in chronic phase chronic myelogenous leukemia patients after imatinib failure according to baseline BCR-ABL mutations. J Clin Oncol 2007;25: abstact 7023
   Web of Science ®Google Scholar
• Shah NP, Tran C, Lee FY, Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399-401
   PubMed Web of Science ®Google Scholar
• Burgess MR, Skaggs BJ, Shah NP, Comparative analysis of two clinically active BCR–ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci USA 2005;102:3395-400
   PubMed Web of Science ®Google Scholar
• Donato NJ, Wu JY, Stapley J, BCR–ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003;101:690-8
   PubMed Web of Science ®Google Scholar
• Li S. Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk Lymphoma 2008;49:19-26
   PubMed Web of Science ®Google Scholar
• Ingley E. Src family kinases: regulation of their activities, levels and identification of new pathways. Biochim Biophys Acta 2008;1784:56-65
   PubMed Web of Science ®Google Scholar
• Stanglmaier M, Warmuth M, Kleinlein I, The interaction of the BCR–ABL tyrosine kinase with the Src kinase Hck is mediated by multiple binding domains. Leukemia 2003;17:283-9
   PubMed Web of Science ®Google Scholar
• Klejman A, Schreiner SJ, Nieborowska-Skorska M, The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukaemia cells. EMBO J 2002;21:5766-74
   PubMed Web of Science ®Google Scholar
• Warmuth M, Bergmann M, Priess A, The Src family kinase Hck interacts with BCR–ABL by a kinase-independent mechanism and phosphorylates the Grb2-binding site of Bcr. J Biol Chem 1997;272:33260-70
   PubMed Web of Science ®Google Scholar
• Kappes DJ. CD4 and CD8: hogging all the Lck. Immunity 2007;5:691-3
   Web of Science ®Google Scholar
• Hu Y, Liu Y, Pelletier S, Requirement of Src kinases Lyn, Hck and Fgr for BCR–ABL1?induced B?lymphoblastic leukaemia but not chronic myeloid leukemia. Nature Genet 2004;36:453-61
   PubMed Web of Science ®Google Scholar
• Copland M, Hamilton A, Elrick LJ, Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006;107:4532-9
   PubMed Web of Science ®Google Scholar
• Weisberg E, Manley PW, Breitenstein W, Characterization of AMN107, a selective inhibitor of native and mutant BCR–ABL. Cancer Cell 2005;7:29-141
   Web of Science ®Google Scholar
• Kantarjian H, Giles F, Wunderle L, Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354:2542-51
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Hochhaus A, Cortes J, Nilotinib is highly active and safe in chronic phase chronic myelogenous leukemia (CML-CP) patients with imatinib-resistance or intolerance. ASH Annual Meeting Abstract Book. Blood 2007;110: abstract 735
   Web of Science ®Google Scholar
• le Coutre P, Ottmann OG, Giles F. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 111:1834-9
   PubMed Web of Science ®Google Scholar
• Ottmann O, Larson R, Kantarjian H, Nilotinib monotherapy in patients with imatinib-resistant or -intolerant Ph+ chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL). Haematologica 2007;92: abstract 556
   Web of Science ®Google Scholar
• O'Hare T, Walters DK, Stoffregen EP, In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib resistant Abl kinase domain mutants. Cancer Res 2005;65:4500-5
   PubMed Web of Science ®Google Scholar
• Mueller MC, Erben P, Ernst T, Molecular response according to type of preexisting BCR-ABL mutations after second line dasatinib therapyin chronic phase CML patients. ASH Annual Meeting Abstract Book. Blood 2007;110: abstract 319
   Web of Science ®Google Scholar
• Golas JM, Arndt K, Etienne C, SKI-606, a 4-anilino- 3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res 2003;63:375-81
   PubMed Web of Science ®Google Scholar
• Kimura S, Naito H, Segawa H, NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood 2005;106:3948-54
   PubMed Web of Science ®Google Scholar
• Puttini M, Coluccia AM, Boschelli F, In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib resistant BCR–ABL+ neoplastic cells. Cancer Res 2006;66:11314-22
   PubMed Web of Science ®Google Scholar
• Cortes J, Kantarjian HM, Baccarani M, A phase 1/2 study of SKI-606, a dual Inhibitor of Src and Abl kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphocytic leukemia (ALL) relapsed, refractory or intolerant of imatinib. ASH Annual Meeting Abstract Book. Blood 2006;108: abstract 168
   Google Scholar
• Naito H, Kimura S, Nakaya Y, In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations. Leuk Res 2006;30:1443-6
   PubMed Web of Science ®Google Scholar
• Yokota A, Kimura S, Masuda S, INNO?406, a novel BCR–ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity. Blood 2007;109:306-14
   PubMed Web of Science ®Google Scholar
• Giles FJ, Cortes JE, Jones D, MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007;109:500-2
   PubMed Web of Science ®Google Scholar
• Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nature Rev Mol Cell Biol 2003;4:842-54
   PubMed Web of Science ®Google Scholar
• Carter TA, Wodicka LM, Shah NP, Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 2005;102:11011-6
   PubMed Web of Science ®Google Scholar
• Shah NP, Skaggs B, Branford S, The most common dasatinib-resistant BCR–ABL kinase domain mutations in patients with chronic myeloid leukemia are sensitive to VX-680: rationale for early combination kinase inhibitor therapy. ASH Annual Meeting Abstract Book. Blood 2006;108: abstract 2175
   Google Scholar
• Adrián FJ, Ding Q, Sim T, Allosteric inhibitors of BCR–ABL dependent cell proliferation. Nature Chem Biol 2006;2:95-102
   PubMed Web of Science ®Google Scholar
• Gumireddy K, Baker SJ, Cosenza SC, A non-ATP-competitive inhibitor of BCR–ABL overrides imatinib resistance. Proc Natl Acad Sci USA 2005;102:1992-7
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Cortes J. Omacetaxine mepesuccinate–a semisynthetic formulation of the natural antitumoral alkaloid homoharringtonine, for chronic myelocytic leukemia and other myeloid malignancies. Drugs 2008;5:356-72
   Google Scholar
• Rubio-Viqueira B, Hidalgo M. Targeting mTOR for cancer treatment. Curr Opin Investig Drugs 2006;7:501-12
   PubMed Web of Science ®Google Scholar
• Buchdunger E, Zimmermann J, Mett H, Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res 1996;56:100-4
   PubMed Web of Science ®Google Scholar
• Druker BJ, Tamura S, Buchdunger E, Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6
   PubMed Web of Science ®Google Scholar
• Dierks C, Beigi R, Guo GR, Expansion of BCR-ABL positive leukemic stem cells is dependent on hedgehog pathway activation. Cancer Cell 2008;14:238-49
   PubMed Web of Science ®Google Scholar
• Young MA, Shah NP, Chao, Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the aurora kinase inhibitor VX-680. Cancer Res 2006;66:1007-14
   PubMed Web of Science ®Google Scholar
• Giles FJ, Cortes JE, Jones D, MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood 2007;109:500-2
   PubMed Web of Science ®Google Scholar